Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and...